ACIW vs CLBT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACIW's Piotroski F-Score of 4/9 indicates weak financial health, signaling deterioration in operational efficiency and profitability trends. The company trades at a premium to its Graham Number ($26.81) and intrinsic value ($15.12), suggesting overvaluation despite solid gross margins and ROE. Recent earnings have declined sharply year-over-year (-33.3%) and quarter-over-quarter (-34.7%), with a negative EPS trend and inconsistent beat rates. Insider selling activity, though limited, adds bearish sentiment. Despite strong analyst consensus (strong_buy), technical trends remain bearish and price has underperformed over the past year.
CLBT shows bullish fundamentals based on deterministic rules. Financial strength is strong (F-Score 7/9). Key strengths include strong valuation and growth metrics. Price trades at a 370.1% premium to fair value estimate ($3.01), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
ACIW vs CLBT: Head-to-Head Comparison
This page compares ACI Worldwide, Inc. (ACIW) and Cellebrite DI Ltd. (CLBT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.